COX-2 inhibitors: A review

Pediatric Emergency Care

Volumn 20, Issue 6, 2004, Pages 396-400

  Houston, Avril Melissa ^a   Teach, Stephen J ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

COX 2 inhibitors; Gastrointestinal toxicity; Nonsteroidal anti inflammatory drugs; NSAIDs; Pain control

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PARECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALICYLATE SODIUM; VALDECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; LOW DRUG DOSE; NEPHROTOXICITY; PAIN; PATIENT SELECTION; PEDIATRICS; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 2942753925     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pec.0000133618.36861.73     Document Type: Review

References (47)

1. Lee SS. NSAIDs: mechanism of action. Available at: http://www. uptodateonline.com. Accessed October 8, 2003.
2. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105:31S-38S.
3. Graumlich JF. Preventing gastrointestinal complications of NSAIDs: risk factors, recent advances, and latest strategies. Postgrad Med. 2001;109:117-128.
4. Paloucek FP, Rynn KO. Nonsteroidal anti-inflammatory drugs. In: Ford MD, ed. Clinical Toxicology. WB Saunders; Philadelphia. 2001:281-282.
5. Sperling RI. Eicosanoids in rheumatoid arthritis. Rheum Dis Clin North Am. 1995;21:741.
6. Penrose JF. Physiology of lipid mediators (prostaglandins; leukotrienes; and lipoxins) and their role in inflammation. Available at: http://www. uptodateonline.com. Accessed October 8, 2003.
7. Lee SS. COX-2 inhibitors: are they nonsteroidal anti-inflammatory drugs with a better safety profile? Gastroenterol Clin North Am. 2001;30:1011-1025.
8. Noble SL, King DS, Olutade JI. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Phys. 2000;61:3669-3676.
9. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
10. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med. 1994;96:274-281.
11. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin North Am. 1996;6:489-504.
12. Scheiman JM. NSAIDs, gastrointestinal injury and cytoprotection. Gastroenterol Clin North Am. 1996;25:279-298.
13. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biologic and clinical application of cyclooxygenase 2. Arthritis Rheum. 2000;43:4-13.
14. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
15. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992;263:F181-F191.
16. Chrischilles EA, Wallace RB. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol. 1993;48: M91-M96.
17. Handel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol. 1997;92:1170-1173.
18. Johnson AG, Simons LA, Simons J, et al. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol. 1993;35:455-459.
19. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1996;98:2076-2085.
20. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13s-24s.
21. Raisz LG, Pilbeam CC, Fall PM. Prostaglandins: mechanisms of action and regulation of production in bone. Osteoporosis Int. 1993;1(suppl): 136-140.
22. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1991;282:1921-1928.
23. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1592-1602.
24. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
25. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
26. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999;65:336-347.
27. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in health adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124-132.
28. Perazella MA, Tray K. Selective cyclooxygenzse-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;111:64-67.
29. FitzGerald FA, Patrono C. Drug therapy: the coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
30. Crofford LJ, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum. 2000;43:1891-1896.
31. Issioui T, Klein KW, White PF, et al. Cost-efficacy of rofecoxib versus acetaminophen for preventing pain after ambulatory surgery. Anesthesiology. 2002;97:931-937.
32. Watcha MR. Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. Anesth Analg. 2003;96:987-994.
33. Maxwell LG, Yaster M. Perioperative management issues in pediatric patients. Anesthesiol Clin North Am. September 2000:18.
34. Turan A. Analgesic effects of rofecoxib in ear-nose-throat surgery. Anesth Analg. 2002;95:1308-1311.
35. Tang J, Li S, White PF, et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology. 2002;96:1305-1309.
36. Redmond M, Florence B, Glass PSA. Effective analgesic modalities for ambulatory patients. Anesthesiol Clin North Am. June 2003:21.
37. Rodgers PE. Office management of trauma: analgesic medications. Clin Fam Pract. September 2000:2.
38. Dugan S, Weber K. Selected topics in sports medicine. Dis Mon. 2002;48:572-616.
39. Lanza FL, Callison DA, Hubbard RC, et al. A pilot endoscopic study of gastroduodenal effects SC-58635, COX-2 selective inhibitor. Arthritis Rheum. 1997;40(suppl):S93.
40. Camu F, Beecher T, Recker DP, et al. Valdecoxib, COX-2 specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther. 2002;9:43-51.
41. Mahutte NG, Arici A. Medical management of endometriosis-associated pain. Obstet Gynecol Clin. 2003;30:133-150.
42. Anand MK, Nelson HS, Dreskin SC. A possible role for cyclooxygenase 2 inhibitors in the treatment of chronic urticaria. J Allergy Clin Immunol. 2003;111:1133-1136.
43. Stempak D, Gammon J, Klein J, et al. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther. 2002;72:490-497.
44. Clergue F, Auroy Y, Pequignot F, et al. French survey of anesthesia in 1996. Anesthesiology. 1999;91:1509-1520.
45. Furst SR, Rodarte A. Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. Anesthesiology. 1994;81:799-803.
46. Warltier DC, Marret E, Flahault A, et al. Effects of postoperative, nonsteroidal, antiinflammatory drugs on bleeding risk after tonsillectomy meta-analysis of randomized, controlled trials. Anesthesiology. June 2003:98.
47. Milojevic DS, Ilowite NT. Treatment of rheumatic diseases in children: special considerations. Rheum Dis Clin North Am. August 2002:28.